Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study

被引:254
作者
Worst, Barbara C. [1 ,2 ,3 ]
van Tilburg, Cornelis M. [2 ,3 ,4 ,5 ]
Balasubramanian, Gnana Prakash [3 ,6 ,7 ]
Fiesel, Petra [3 ,8 ,9 ,12 ]
Witt, Ruth [4 ]
Freitag, Angelika [4 ]
Boudalil, Miream [3 ,8 ,9 ]
Previti, Christopher [10 ]
Wolf, Stephan [10 ]
Schmidt, Sabine [10 ]
Chotewutmontri, Sasithorn [10 ]
Bewerunge-Hudler, Melanie [10 ]
Schick, Matthias [10 ]
Schlesner, Matthias [3 ,11 ]
Hutter, Barbara [3 ,6 ,7 ]
Taylor, Lenka [12 ]
Borst, Tobias [13 ]
Sutter, Christian [14 ]
Bartram, Claus R. [14 ]
Milde, Till [2 ,3 ,5 ]
Pfaff, Elke [1 ,2 ,3 ]
Kulozik, Andreas E. [2 ]
von Stackelberg, Arend [15 ]
Meisel, Roland [16 ]
Borkhardt, Arndt [16 ]
Reinhardt, Dirk [17 ]
Klusmann, Jan-Henning [18 ]
Fleischhack, Gudrun [17 ]
Tippelt, Stephan [17 ]
Dirksen, Uta [19 ]
Juergens, Heribert [19 ]
Kramm, Christof M. [20 ]
von Bueren, Andre O. [20 ,21 ]
Westermann, Frank [3 ,22 ]
Fischer, Matthias [23 ,24 ,25 ]
Burkhardt, Birgit [19 ]
Wossmann, Wilhelm [26 ]
Nathrath, Michaela [27 ,28 ]
Bielack, Stefan S. [29 ]
Fruehwald, Michael C. [30 ]
Fulda, Simone [3 ,31 ]
Klingebiel, Thomas [32 ]
Koscielniak, Ewa [29 ]
Schwab, Matthias [3 ,33 ,34 ,35 ]
Tremmel, Roman [33 ,34 ,35 ]
Driever, Pablo Hernaiz [15 ]
Schulte, Johannes H. [15 ,17 ]
Brors, Benedikt [3 ,6 ,7 ]
von Deimling, Andreas [3 ,8 ,9 ]
Lichter, Peter [3 ,36 ]
机构
[1] German Canc Res Ctr, Div Pediat Neurooncol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany
[2] Univ Heidelberg Hosp, Dept Pediat Oncol Hematol & Immunol, Neuenheimer Feld 430, D-69120 Heidelberg, Germany
[3] German Canc Consortium DKTK, Neuenheimer Feld 280, D-69120 Heidelberg, Germany
[4] Natl Ctr Tumor Dis, NCT Trial Ctr, Neuenheimer Feld 130-3, D-69120 Heidelberg, Germany
[5] German Canc Res Ctr, Clin Cooperat Unit Pediat Oncol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany
[6] German Canc Res Ctr, Div Appl Bioinformat, Neuenheimer Feld 280, D-69120 Heidelberg, Germany
[7] Natl Ctr Tumor Dis NCT, Neuenheimer Feld 460, D-69120 Heidelberg, Germany
[8] Univ Heidelberg Hosp, Dept Neuropathol, Neuenheimer Feld 224, D-69120 Heidelberg, Germany
[9] German Canc Res Ctr, Clin Cooperat Unit Neuropathol, Neuenheimer Feld 224, D-69120 Heidelberg, Germany
[10] German Canc Res Ctr, Genom & Prote Core Facil, Neuenheimer Feld 280, D-69120 Heidelberg, Germany
[11] German Canc Res Ctr, Div Theoret Bioinformat, Neuenheimer Feld 280, D-69120 Heidelberg, Germany
[12] Univ Heidelberg Hosp, Dept Pharm, Neuenheimer Feld 670, D-69120 Heidelberg, Germany
[13] Erlangen Univ Hosp, Dept Pharm, Palmsanlage 3, D-91054 Erlangen, Germany
[14] Univ Heidelberg Hosp, Inst Human Genet, Neuenheimer Feld 366, D-69120 Heidelberg, Germany
[15] Charite, Dept Pediat Oncol & Hematol, Augustenburger Pl 1, D-13353 Berlin, Germany
[16] Dusseldorf Univ Hosp, Dept Pediat Oncol Hematol & Clin Immunol, Fac Med, Moorenstr 5, D-40225 Dusseldorf, Germany
[17] Univ Hosp Essen, Pediat 3, Pediat Oncol & Hematol, Hufelandstr 55, D-45147 Essen, Germany
[18] Hannover Med Sch, Dept Pediat Hematol & Oncol, Carl Neuberg Str 1, D-30625 Hannover, Germany
[19] Univ Hosp Munster, Dept Pediat Hematol & Oncol, Albert Schweitzer Campus 1, D-48149 Munster, Germany
[20] Univ Med Ctr Gottingen, Div Pediat Hematol & Oncol, Robert Koch Str 40, D-37075 Gottingen, Germany
[21] Univ Hosp Geneva, Div Pediat Hematol & Oncol, Dept Pediat & Adolescent Med, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland
[22] German Canc Res Ctr, Div Neuroblastoma Genom, Neuenheimer Feld 280, D-69120 Heidelberg, Germany
[23] Univ Hosp Cologne, Dept Pediat Hematol & Oncol, Kerpener Str 62, D-50937 Cologne, Germany
[24] Univ Cologne, Fac Med, CMMC, Robert Koch Str 21, D-50931 Cologne, Germany
[25] Max Planck Inst Metab Res, Gleueler Str 50, D-50931 Cologne, Germany
[26] Univ Hosp Giessen, Dept Pediat Hematol & Oncol, Feulgenstr 12, D-35392 Giessen, Germany
[27] Klinikum Kassel, Dept Pediat Oncol, Monchebergstr 41-43, D-34125 Kassel, Germany
[28] Tech Univ Munich, Pediat Oncol Ctr, Kolner Pl 1, D-80804 Munich, Germany
[29] Klinikum Stuttgart Olgahosp, Dept Pediat Oncol Hematol & Immunol, Kriegsbergstr 62, D-70174 Stuttgart, Germany
[30] Klinikum Augsburg, Childrens Hosp, Swabian Childrens Canc Ctr, Stenglinstr 2, D-86156 Augsburg, Germany
[31] Univ Hosp Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Germany
[32] Univ Hosp Frankfurt, Dept Pediat Oncol & Hematol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany
[33] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Auerbachstr 112, D-70376 Stuttgart, Germany
[34] Univ Tubingen, Dept Clin Pharmacol, Morgenstelle 8, D-72076 Tubingen, Germany
[35] Univ Tubingen, Dept Biochem & Pharm, Morgenstelle 8, D-72076 Tubingen, Germany
[36] German Canc Res Ctr, Div Mol Genet, Neuenheimer Feld 280, D-69120 Heidelberg, Germany
关键词
Personalised medicine; Oncology; Paediatrics; Precision medicine; Molecular targeted therapy; Deep sequencing; Cancer; Sarcoma; Brain; RETROSPECTIVE ANALYSIS; DRUG RESPONSE; PHASE-I; THERAPY; RELAPSE; ADOLESCENTS; RECURRENCE; ONCOLOGY; CHILDREN; SURVIVAL;
D O I
10.1016/j.ejca.2016.06.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The 'Individualized Therapy for Relapsed Malignancies in Childhood' (INFORM) precision medicine study is a nationwide German program for children with high-risk relapsed/refractory malignancies, which aims to identify therapeutic targets on an individualised basis. In a pilot phase, reported here, we developed the logistical and analytical pipelines necessary for rapid and comprehensive molecular profiling in a clinical setting. Fifty-seven patients from 20 centers were prospectively recruited. Malignancies investigated included sarcomas (n = 25), brain tumours (n = 23), and others (n = 9). Whole-exome, low-coverage whole-genome, and RNA sequencing were complemented with methylation and expression microarray analyses. Alterations were assessed for potential targetability according to a customised prioritisation algorithm and subsequently discussed in an interdisciplinary molecular tumour board. Next-generation sequencing data were generated for 52 patients, with the full analysis possible in 46 of 52. Turnaround time from sample receipt until first report averaged 28 d. Twenty-six patients (50%) harbored a potentially druggable alteration with a prioritisation score of 'intermediate' or higher (level 4 of 7). Common targets included receptor tyrosine kinases, phosphoinositide 3-kinase-mammalian target of rapamycin pathway, mitogen-activated protein kinase pathway, and cell cycle control. Ten patients received a targeted therapy based on these findings, with responses observed in some previously treatment-refractory tumours. Comparative primary relapse analysis revealed substantial tumour evolution as well as one case of unsuspected secondary malignancy, highlighting the importance of re-biopsy at relapse. This study demonstrates the feasibility of comprehensive, real-time molecular profiling for high-risk paediatric cancer patients. This extended proof-of-concept, with examples of treatment consequences, expands upon previous personalised oncology endeavors, and presents a model with considerable interest and practical relevance in the burgeoning era of personalised medicine. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:91 / 101
页数:11
相关论文
共 38 条
[1]   A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing [J].
Alioto, Tyler S. ;
Buchhalter, Ivo ;
Derdak, Sophia ;
Hutter, Barbara ;
Eldridge, Matthew D. ;
Hovig, Eivind ;
Heisler, Lawrence E. ;
Beck, Timothy A. ;
Simpson, Jared T. ;
Tonon, Laurie ;
Sertier, Anne-Sophie ;
Patch, Ann-Marie ;
Jaeger, Natalie ;
Ginsbach, Philip ;
Drews, Ruben ;
Paramasivam, Nagarajan ;
Kabbe, Rolf ;
Chotewutmontri, Sasithorn ;
Diessl, Nicolle ;
Previti, Christopher ;
Schmidt, Sabine ;
Brors, Benedikt ;
Feuerbach, Lars ;
Heinold, Michael ;
Groebner, Susanne ;
Korshunov, Andrey ;
Tarpey, Patrick S. ;
Butler, Adam P. ;
Hinton, Jonathan ;
Jones, David ;
Menzies, Andrew ;
Raine, Keiran ;
Shepherd, Rebecca ;
Stebbings, Lucy ;
Teague, Jon W. ;
Ribeca, Paolo ;
Giner, Francesc Castro ;
Beltran, Sergi ;
Raineri, Emanuele ;
Dabad, Marc ;
Heath, Simon C. ;
Gut, Marta ;
Denroche, Robert E. ;
Harding, Nicholas J. ;
Yamaguchi, Takafumi N. ;
Fujimoto, Akihiro ;
Nakagawa, Hidewaki ;
Quesada, Ctor ;
Valdes-Mas, Rafael ;
Nakken, Sigve .
NATURE COMMUNICATIONS, 2015, 6
[2]   A Retrospective Analysis of Recurrent Intracranial Ependymoma [J].
Antony, Reuben ;
Wong, Kenneth E. ;
Patel, Moneil ;
Olch, Arthur J. ;
McComb, Gordon ;
Krieger, Mark ;
Gilles, Floyd ;
Sposto, Richard ;
Erdreich-Epstein, Anat ;
Dhall, Girish ;
Gardner, Sharon ;
Finlay, Jonathan L. .
PEDIATRIC BLOOD & CANCER, 2014, 61 (07) :1195-1201
[3]   Childhood Atypical Teratoid Rhabdoid Tumor of the Central Nervous System A Meta-Analysis of Observational Studies [J].
Athale, Uma H. ;
Duckworth, JoAnn ;
Odame, Isaac ;
Barr, Ronald .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2009, 31 (09) :651-663
[4]   Patients in Pediatric Phase I and Early Phase II Clinical Oncology Trials at Gustave Roussy: A 13-Year Center Experience [J].
Bautista, Francisco ;
Di Giannatale, Angela ;
Dias-Gastellier, Nathalie ;
Fahd, Mony ;
Valteau-Couanet, Dominique ;
Couanet, Dominique ;
Grill, Jacques ;
Brugieres, Laurence ;
Dufour, Christelle ;
Gaspar, Nathalie ;
Minard-Colin, Veronique ;
Kalifa, Chantal ;
Oberlin, Odile ;
Patte, Catherine ;
Vassal, Gilles ;
Geoerger, Birgit .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2015, 37 (02) :E102-E110
[5]   Translating genomic discoveries to the clinic in pediatric oncology [J].
Bender, Julia Glade ;
Verma, Anupam ;
Schiffman, Joshua D. .
CURRENT OPINION IN PEDIATRICS, 2015, 27 (01) :34-43
[6]   Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma [J].
Cin, Huriye ;
Meyer, Claus ;
Herr, Ricarda ;
Janzarik, Wibke G. ;
Lambert, Sally ;
Jones, David T. W. ;
Jacob, Karine ;
Benner, Axel ;
Witt, Hendrik ;
Remke, Marc ;
Bender, Sebastian ;
Falkenstein, Fabian ;
Ton Nu Van Anh ;
Olbrich, Heike ;
von Deimling, Andreas ;
Pekrun, Arnulf ;
Kulozik, Andreas E. ;
Gnekow, Astrid ;
Scheurlen, Wolfram ;
Witt, Olaf ;
Omran, Heymut ;
Jabado, Nada ;
Collins, V. Peter ;
Brummer, Tilman ;
Marschalek, Rolf ;
Lichter, Peter ;
Korshunov, Andrey ;
Pfister, Stefan M. .
ACTA NEUROPATHOLOGICA, 2011, 121 (06) :763-774
[7]   The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01 [J].
Creutzig, Ursula ;
Zimmermann, Martin ;
Dworzak, Michael N. ;
Gibson, Brenda ;
Tamminga, Rienk ;
Abrahamsson, Jonas ;
Ha, Shau-Yin ;
Hasle, Henrik ;
Maschan, Alexey ;
Bertrand, Yves ;
Leverger, Guy ;
von Neuhoff, Christine ;
Razzouk, Bassem ;
Rizzari, Carmelo ;
Smisek, Petr ;
Smith, Owen P. ;
Stark, Batia ;
Reinhardt, Dirk ;
Kaspers, Gertjan L. .
HAEMATOLOGICA, 2014, 99 (09) :1472-1478
[8]  
Ferte C, 2014, CANC RES S, V74
[9]   Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5-a population-based study [J].
Gatta, Gemma ;
Botta, Laura ;
Rossi, Silvia ;
Aareleid, Tiiu ;
Bielska-Lasota, Magdalena ;
Clavel, Jacqueline ;
Dimitrova, Nadya ;
Jakab, Zsuzsanna ;
Kaatsch, Peter ;
Lacour, Brigitte ;
Mallone, Sandra ;
Marcos-Gragera, Rafael ;
Minicozzi, Pamela ;
Sanchez-Perez, Maria-Jose ;
Sant, Milena ;
Santaquilani, Mariano ;
Stiller, Charles ;
Tavilla, Andrea ;
Trama, Annalisa ;
Visser, Otto ;
Peris-Bonet, Rafael .
LANCET ONCOLOGY, 2014, 15 (01) :35-47
[10]   Towards a European consensus for reporting incidental findings during clinical NGS testing [J].
Hehir-Kwa, Jayne Y. ;
Claustres, Mireille ;
Hastings, Ros J. ;
van Ravenswaaij-Arts, Conny ;
Christenhusz, Gabrielle ;
Genuardi, Maurizio ;
Melegh, Bela ;
Cambon-Thomsen, Anne ;
Patsalis, Philippos ;
Vermeesch, Joris ;
Cornel, Martina C. ;
Searle, Beverly ;
Palotie, Aarno ;
Capoluongo, Ettore ;
Peterlin, Borut ;
Estivill, Xavier ;
Robinson, Peter N. .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2015, 23 (12) :1601-1606